2005
DOI: 10.1016/j.jsbmb.2005.05.003
|View full text |Cite
|
Sign up to set email alerts
|

Orexins stimulate glucocorticoid secretion from cultured rat and human adrenocortical cells, exclusively acting via the OX1 receptor

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
44
0

Year Published

2006
2006
2022
2022

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 47 publications
(46 citation statements)
references
References 53 publications
2
44
0
Order By: Relevance
“…It was previously suggested that specific glucocorticoid secretion in response to orexin in adrenal cells was restricted to PKA-dependent pathways acting exclusively through OX1R (Ziolkowska et al 2005). In our human adrenal cell line, the effects on MAPK activation of ORA and ORB were roughly comparable.…”
Section: Discussionsupporting
confidence: 52%
See 1 more Smart Citation
“…It was previously suggested that specific glucocorticoid secretion in response to orexin in adrenal cells was restricted to PKA-dependent pathways acting exclusively through OX1R (Ziolkowska et al 2005). In our human adrenal cell line, the effects on MAPK activation of ORA and ORB were roughly comparable.…”
Section: Discussionsupporting
confidence: 52%
“…Evidence for dominant effects of OX1R in the adrenal cells has been observed (Ziolkowska et al 2005), but mRNA has been shown for both OX1R and OX2R in these cells (Ramanjaneya et al 2008). …”
Section: Resultsmentioning
confidence: 99%
“…To date, compelling evidence indicates an interaction of the orexin system with the hypothalamuspituitary-adrenal (HPA) axis on a central, as well as peripheral level (6). Orexins (10 -10 to 10 -6 M) exert a stimulatory effect on glucocorticoid release, adrenocortical cell growth and, in some cases, mineralocorticoid release from the adrenal cortex of various species (7)(8)(9)(10)(11)(12)(13). This fact seems to be related to orexin-A (10 -6 M) enhancing the expression of 3β-hydroxysteroid dehydrogenase (3β-HSD) (14).…”
Section: Introductionmentioning
confidence: 99%
“…Surely, in vivo investigations on this topic could take advantage of the use of animals in which endogenous orexin system is stably suppressed (e.g., orexin gene knockout animals). So far immunoblockade of orexin receptors with specific antibodies has been used in in vitro experiments (Spinazzi et al, 2005c;Ziolkowska et al, 2005), but this approach is unfeasible in long-term in vivo experiments. Furthermore, at present, only a selective not yet commercially available OX1-R nonpeptide antagonist (SB-334867) has been synthesized Smart et al, 2001).…”
Section: Discussionmentioning
confidence: 99%